products:

  PRODUCT INDICATION

  ELIQUIS (Apixaban) For the prevention and treatment of venous thromboembolism, which is being developed in collaboration with BMS

  Eraxis/Vfend Combination Aspergillosis fungal infections

  INLYTA (Axitinib) Oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptor 1, 2 & 3 for the treatment of renal cell carcinoma in treatment-naïve patients

Lyrica     Peripheral neuropathic pain; CR (once-a-day) dosing

Sutent     Adjuvant renal cell carcinoma

Tofacitinib     A JAK kinase inhibitor for the treatment of psoriasis

  Torisel Renal cell carcinoma 2nd line

  Xalkori (Crizotinib) An oral ALK and c-Met inhibitor for the treatment of ALK-positive 1st and 2nd line non-small cell lung cancer

Xiapex     Peyronie’s disease

  Zithromax/chloroquine Malaria

In October 2011, an independent Data Monitoring Committee (DMC) for a Phase 3 efficacy and safety study of Lyrica as monotherapy for epilepsy patients with partial onset seizures recommended that the study be stopped based on positive findings for the primary efficacy endpoint. We have accepted the DMC’s recommendation and stopped the study. We intend to submit the results of the study for publication in a medical journal. We do not intend to seek an indication for Lyrica as monotherapy for epilepsy patients with partial onset seizures.

 New drug candidates in late-stage development:

  CANDIDATE INDICATION

  ALO-02 A Mu-type opioid receptor agonist for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time

  Bapineuzumab(a) A beta amyloid inhibitor for the treatment of mild-to-moderate Alzheimer’s disease being developed in collaboration with Janssen Alzheimer Immunotherapy Research & Development, LLC (Janssen AI),

a subsidiary of Johnson & Johnson

  Bazedoxifene-conjugated A tissue-selective estrogen complex for the treatment of menopausal vasomotor symptoms estrogens

Dacomitinib     A pan-HER tyrosine kinase inhibitor for the treatment of advanced non-small cell lung cancer

  Inotuzumab ozogamicin An antibody drug conjugate, consisting of an anti-CD22 monotherapy antibody linked to a cytotoxic agent, calicheamycin, for the treatment of aggressive Non-Hodgkin’s Lymphoma

  Tanezumab(b) An anti-nerve growth factor monoclonal antibody for the treatment of pain (on clinical hold)

(a) Our collaboration with Janssen AI on bapineuzumab, a potential treatment for mild-to-moderate Alzheimer’s disease, continues with four Phase 3 studies. In December 2010, Janssen AI confirmed that enrollment was complete for its two Phase 3 primarily North American studies (301 and 302), including the biomarker sub-studies. The other two Phase 3 primarily international studies (3000 and 3001) continue to enroll. Johnson & Johnson expects that the two Janssen AI primarily North American studies will be completed (last patient out) in mid-2012. We expect that the last patient will have completed our two primarily international 18-month trials, including associated biomarker studies, in 2014.

(b) Following requests by the FDA in 2010, we suspended and subsequently